White Paper:
Process Validation and Regulatory Review in the Age of Expedited Approval Drugs
Expedited approval drugs have profoundly changed the thinking and approach to Process Validation and other CMC activities. When working on the development of an expedited approval drug, Chemistry, Manufacturing and Controls (CMC) data needs to be generated in about half the time of the traditional process.
Of course, an expedited approval classification does not mean that the drug developer can do less. In order to meet these accelerated timelines, analytical methods creation and product and process characterization needs to start sooner, and the process needs to be handled differently.
This paper explores those dynamics and offers some revised approach suggestions.
Download the Whitepaper
Complete the form below to download your copy!
You might also be interested in…
eBook: Key Considerations in Gene Therapy Manufacturing for Commercialization
eBook: Key Considerations in Gene Therapy Manufacturing for Commercialization “The regulatory landscape for gene therapies is as transforming as the curative nature of a transgene. In 2012, we saw the introduction of the Breakthrough Therapy Designation. Just when you...
White Paper: 4 Things You Need to Know About Combination Drug Compliance
White Paper: 4 Things You Need to Know About Combination Drug ComplianceCombination products are a fascinating area of the pharmaceutical industry and present great future promise. The segment is projected to reach $115 billion in global sales by the end of 2019. It...
White Paper: 4 Steps for Managing Biopharmaceutical Projects
White Paper: White Paper: 4 Steps for Managing Biopharmaceutical Projects By Tracy TreDenick, Head of Regulatory and Quality, and Senior Consultant, and Julie Spyrison Associate Director, Regulatory Operations at BioTechLogic, Inc. The global biopharmaceutical market...